Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Common Stock Valuation Ratios (Price Multiples) 
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Merck & Co. Inc., historical price multiples (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Price to earnings (P/E) 16.79 11.00 12.30 11.98 13.49 20.98 20.73 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70
Price to operating profit (P/OP) 14.44 9.67 10.57 10.37 11.60 18.67 18.41 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29
Price to sales (P/S) 4.71 3.26 3.17 3.27 3.60 4.03 4.56 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12
Price to book value (P/BV) 5.82 4.04 4.12 4.32 4.99 5.73 6.53 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The valuation ratios exhibit considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values generally trended upward through the first half of 2022, followed by periods of volatility and, in some cases, significant increases in late 2022 and early 2023. More recently, a general trend towards lower ratios is apparent, though with continued quarterly variation.

Price to Earnings (P/E) Ratio
The P/E ratio began at 15.70 and increased to 22.92 by March 2023. A substantial spike occurred in June 2023, reaching 86.53, followed by an exceptionally high value of 893.99 in December 2023. Subsequently, the ratio decreased significantly, falling to 11.98 by March 2025, before rising again to 16.79 by the end of the period. This indicates substantial earnings volatility or shifts in investor sentiment.
Price to Operating Profit (P/OP) Ratio
The P/OP ratio mirrored the P/E ratio’s initial upward trend, increasing from 14.29 to 18.53 by March 2023. Similar to the P/E ratio, a marked increase was observed in June 2023 (44.67) and December 2023 (138.56), followed by a decline to 10.37 in March 2025, and a final increase to 14.44 by December 2025. The correlation with the P/E ratio suggests a strong relationship between earnings and operating profit.
Price to Sales (P/S) Ratio
The P/S ratio demonstrated a more moderate pattern of change. It increased from 4.12 in March 2022 to 5.16 in March 2023, then fluctuated between 4.42 and 5.43 before decreasing to 3.17 in June 2025. A final increase to 4.71 was observed in December 2025. This suggests a relatively stable relationship between price and revenue, though with some recent downward pressure.
Price to Book Value (P/BV) Ratio
The P/BV ratio consistently increased from 5.44 in March 2022 to 6.96 in June 2023, peaking at 8.68 in December 2023. A subsequent and consistent decline was observed, reaching 4.04 in September 2025, before increasing to 5.82 in December 2025. This suggests a decreasing premium investors are willing to pay for the net asset value of the company, followed by a slight recovery at the end of the period.

Overall, the observed ratios indicate a period of significant volatility, particularly in the P/E and P/OP ratios. The substantial increases in these ratios during late 2022 and early 2023, followed by declines, warrant further investigation to understand the underlying drivers of these changes. The P/S and P/BV ratios exhibited more moderate fluctuations, but still demonstrate a recent trend towards lower valuations.


Price to Earnings (P/E)

Merck & Co. Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 2,472,392,003 2,482,022,536 2,497,783,211 2,511,031,253 2,526,036,240 2,529,635,645 2,534,809,312 2,532,806,307 2,532,643,872 2,534,023,084 2,537,521,169 2,537,435,954 2,538,592,467 2,535,395,974 2,533,279,845 2,528,805,025
Selected Financial Data (US$)
Net income (loss) attributable to Merck & Co., Inc. (in millions) 2,963 5,785 4,427 5,079 3,743 3,157 5,455 4,762 (1,226) 4,745 (5,975) 2,821 3,017 3,248 3,944 4,310
Earnings per share (EPS)2 7.38 7.67 6.57 6.94 6.78 4.80 5.42 0.91 0.14 1.82 1.23 5.14 5.72 6.02 6.54 5.61
Share price1, 3 123.93 84.39 80.79 83.18 91.43 100.73 112.31 127.51 128.84 103.38 106.09 117.68 109.89 98.75 87.41 88.01
Valuation Ratio
P/E ratio4 16.79 11.00 12.30 11.98 13.49 20.98 20.73 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 94.06 159.78 92.57 77.73 79.59 69.16 62.04 48.26 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64
Amgen Inc. 25.81 24.59 23.15 25.49 38.24 40.68 53.65 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23
Bristol-Myers Squibb Co. 17.30 15.38 17.46 18.29 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64
Danaher Corp. 40.93 44.52 39.84 36.51 38.12 48.49 45.39 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15
Eli Lilly & Co. 47.45 43.36 43.95 67.76 77.63 96.05 109.42 120.94 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29
Gilead Sciences Inc. 21.54 18.18 21.68 20.62 296.57 925.87 89.29 166.76 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25
Johnson & Johnson 21.66 18.51 18.02 17.14 26.92 27.19 10.11 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95
Pfizer Inc. 19.83 14.06 13.09 17.22 18.42 37.00 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11
Regeneron Pharmaceuticals Inc. 18.19 15.03 13.29 13.65 17.76 19.79 27.88 26.78 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15
Thermo Fisher Scientific Inc. 28.82 32.45 26.56 24.55 32.03 34.78 37.81 36.21 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15
Vertex Pharmaceuticals Inc. 31.58 29.11 26.43 26.34 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
EPS = (Net income (loss) attributable to Merck & Co., Inc.Q4 2025 + Net income (loss) attributable to Merck & Co., Inc.Q3 2025 + Net income (loss) attributable to Merck & Co., Inc.Q2 2025 + Net income (loss) attributable to Merck & Co., Inc.Q1 2025) ÷ No. shares of common stock outstanding
= (2,963,000,000 + 5,785,000,000 + 4,427,000,000 + 5,079,000,000) ÷ 2,472,392,003 = 7.38

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= 123.93 ÷ 7.38 = 16.79

5 Click competitor name to see calculations.


The price to earnings (P/E) ratio exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a relatively stable range, followed by periods of significant volatility and a concluding trend towards increased values.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The P/E ratio began at 15.70 and demonstrated a moderate increase, peaking at 19.21 by December 31, 2022. This period suggests a generally positive investor sentiment, with the share price increasing alongside earnings per share (EPS), resulting in a rising, but contained, valuation multiple.
Volatility and Extreme Values (Mar 31, 2023 – Dec 31, 2023)
A dramatic shift occurred in the subsequent quarters. The P/E ratio surged to an exceptionally high value of 893.99 by December 31, 2023. This spike was primarily driven by a substantial decrease in EPS, while the share price remained relatively elevated. The period between March 31, 2023 and December 31, 2023 shows a clear divergence between share price and earnings, indicating a potential overvaluation or market anticipation of future earnings growth that did not immediately materialize. The ratio reached 86.53 in June 2023 and 56.85 in September 2023, demonstrating continued high volatility.
Correction and Stabilization (Mar 31, 2024 – Jun 30, 2025)
Following the peak, the P/E ratio experienced a significant correction, decreasing to 13.49 by December 31, 2024. This decline coincided with both a decrease in share price and an increase in EPS. The ratio then stabilized in the range of 11.00 to 16.79 through June 30, 2025, suggesting a return to more normalized valuation levels. The final reported value, 16.79, indicates a moderate increase from the preceding quarters, potentially reflecting renewed investor confidence or expectations of future earnings improvements.

Overall, the P/E ratio demonstrated a complex pattern characterized by initial stability, a period of extreme volatility linked to earnings fluctuations, and a subsequent correction towards a more moderate valuation. The substantial increase in the ratio during 2023 warrants further investigation to understand the underlying market dynamics and investor expectations during that period.


Price to Operating Profit (P/OP)

Merck & Co. Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 2,472,392,003 2,482,022,536 2,497,783,211 2,511,031,253 2,526,036,240 2,529,635,645 2,534,809,312 2,532,806,307 2,532,643,872 2,534,023,084 2,537,521,169 2,537,435,954 2,538,592,467 2,535,395,974 2,533,279,845 2,528,805,025
Selected Financial Data (US$)
Operating income (loss) (in millions) 3,851 6,507 4,992 5,868 4,299 3,928 6,048 5,637 (1,967) 5,746 (5,163) 3,739 3,439 4,012 4,925 5,569
Operating profit per share2 8.58 8.73 7.64 8.02 7.88 5.39 6.10 1.68 0.93 3.06 2.38 6.35 7.07 7.13 7.46 6.16
Share price1, 3 123.93 84.39 80.79 83.18 91.43 100.73 112.31 127.51 128.84 103.38 106.09 117.68 109.89 98.75 87.41 88.01
Valuation Ratio
P/OP ratio4 14.44 9.67 10.57 10.37 11.60 18.67 18.41 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 26.37 42.20 31.76 32.37 37.26 25.63 26.99 22.62 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57
Amgen Inc. 21.92 19.86 18.71 20.31 21.55 27.68 27.12 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88
Bristol-Myers Squibb Co. 12.20 10.25 11.07 13.65 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32
Danaher Corp. 31.54 33.80 30.79 28.49 30.56 39.52 38.14 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48
Eli Lilly & Co. 37.24 34.60 35.19 53.43 63.73 79.30 88.66 99.34 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49
Gilead Sciences Inc. 18.29 14.06 17.00 14.96 85.65 143.05 36.80 51.26 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78
Johnson & Johnson 22.95 19.83 19.04 17.74 18.20 18.65 17.54 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06
Pfizer Inc. 10.82 10.07 9.49 11.27 11.92 27.24 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49
Regeneron Pharmaceuticals Inc. 22.90 18.65 15.42 16.03 19.63 23.18 30.86 26.82 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98
Thermo Fisher Scientific Inc. 24.94 28.40 23.62 21.64 27.65 29.74 32.66 31.40 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84
Vertex Pharmaceuticals Inc. 29.92 26.79 24.50 25.25 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Operating profit per share = (Operating income (loss)Q4 2025 + Operating income (loss)Q3 2025 + Operating income (loss)Q2 2025 + Operating income (loss)Q1 2025) ÷ No. shares of common stock outstanding
= (3,851,000,000 + 6,507,000,000 + 4,992,000,000 + 5,868,000,000) ÷ 2,472,392,003 = 8.58

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 123.93 ÷ 8.58 = 14.44

5 Click competitor name to see calculations.


The Price to Operating Profit (P/OP) ratio exhibits considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicate a relatively stable range, followed by significant volatility and a subsequent return towards earlier levels.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The P/OP ratio began at 14.29 and generally increased, reaching 15.55 by the end of 2022. This suggests a growing investor willingness to pay a premium for each dollar of operating profit during this timeframe. The ratio remained within a narrow band, indicating moderate stability.
Significant Volatility (Mar 31, 2023 – Dec 31, 2023)
A dramatic increase in the P/OP ratio is observed starting in the first quarter of 2023, peaking at 138.56 in December 2023. This surge coincided with a substantial decrease in operating profit per share, particularly in the latter half of the year, indicating a potentially speculative market reaction or a temporary disruption in earnings. The ratio then declined sharply to 75.94 in March 2024.
Stabilization and Decline (Mar 31, 2024 – Dec 31, 2024)
Following the peak, the P/OP ratio experienced a considerable decline, reaching 11.60 by December 2024. This decrease suggests a correction in market valuation, potentially reflecting improved operating profit per share and a more rational assessment of the company’s earnings potential. The ratio fluctuated between 18.41 and 11.60 during this period.
Recent Trend (Mar 31, 2025 – Dec 31, 2025)
The P/OP ratio demonstrated relative stability in the first three quarters of 2025, ranging from 10.37 to 9.67. A notable increase to 14.44 occurred in December 2025, coinciding with an increase in operating profit per share, suggesting renewed investor confidence. This final value is comparable to the levels observed in the initial period of the analysis.

Overall, the P/OP ratio demonstrates a cyclical pattern with periods of growth, extreme volatility, and subsequent correction. The significant spike in 2023 warrants further investigation to understand the underlying drivers of this market behavior. The recent stabilization and slight increase suggest a potential return to more sustainable valuation levels.


Price to Sales (P/S)

Merck & Co. Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 2,472,392,003 2,482,022,536 2,497,783,211 2,511,031,253 2,526,036,240 2,529,635,645 2,534,809,312 2,532,806,307 2,532,643,872 2,534,023,084 2,537,521,169 2,537,435,954 2,538,592,467 2,535,395,974 2,533,279,845 2,528,805,025
Selected Financial Data (US$)
Sales (in millions) 16,400 17,276 15,806 15,529 15,624 16,657 16,112 15,775 14,631 15,962 15,035 14,487 13,830 14,959 14,593 15,901
Sales per share2 26.29 25.88 25.47 25.46 25.40 24.97 24.65 24.24 23.74 23.41 22.98 22.81 23.35 23.26 22.57 21.35
Share price1, 3 123.93 84.39 80.79 83.18 91.43 100.73 112.31 127.51 128.84 103.38 106.09 117.68 109.89 98.75 87.41 88.01
Valuation Ratio
P/S ratio4 4.71 3.26 3.17 3.27 3.60 4.03 4.56 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 6.50 6.40 5.97 5.68 6.04 6.38 6.02 5.32 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76
Amgen Inc. 5.66 4.99 4.57 4.61 4.88 5.53 5.68 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21
Bristol-Myers Squibb Co. 2.53 1.93 1.85 2.08 2.36 2.38 2.20 1.99 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41
Danaher Corp. 6.02 6.43 5.66 5.77 6.23 7.95 8.10 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68
Eli Lilly & Co. 15.03 13.44 11.39 15.36 18.25 19.67 20.64 20.66 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47
Gilead Sciences Inc. 6.34 5.16 4.76 4.31 4.98 4.18 3.41 2.97 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86
Johnson & Johnson 6.16 5.04 4.51 4.19 4.26 4.55 4.44 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00
Pfizer Inc. 2.46 2.20 2.20 2.17 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00
Regeneron Pharmaceuticals Inc. 5.71 4.83 4.17 4.36 5.52 6.65 8.93 7.89 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40
Thermo Fisher Scientific Inc. 4.34 4.87 4.05 3.73 4.73 5.04 5.55 5.14 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20
Vertex Pharmaceuticals Inc. 10.40 9.13 8.42 10.41 10.78 12.12 12.35 10.39 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Sales per share = (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025) ÷ No. shares of common stock outstanding
= (16,400,000,000 + 17,276,000,000 + 15,806,000,000 + 15,529,000,000) ÷ 2,472,392,003 = 26.29

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= 123.93 ÷ 26.29 = 4.71

5 Click competitor name to see calculations.


The price-to-sales (P/S) ratio exhibited fluctuating behavior over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a moderate ratio, followed by periods of increase and decrease, ultimately concluding with a value comparable to that observed in late 2022.

Initial Period (Mar 31, 2022 – Dec 31, 2022)
The P/S ratio began at 4.12 and generally increased, reaching a peak of 4.71 by December 31, 2022. This suggests a growing investor willingness to pay more for each dollar of sales during this timeframe. The share price increased from US$88.01 to US$109.89, while sales per share remained relatively stable, contributing to the ratio’s rise.
Fluctuation and Decline (Mar 31, 2023 – Dec 31, 2023)
The first half of 2023 saw a decrease to 4.62, followed by a substantial increase to 5.43 by the end of the year. This period was characterized by volatility in the share price, moving from US$117.68 to US$128.84, and a modest increase in sales per share. The significant rise in the ratio towards the end of 2023 indicates renewed investor optimism or a potential overvaluation relative to sales.
Downward Trend (Mar 31, 2024 – Jun 30, 2025)
A consistent downward trend was observed in the P/S ratio from 5.26 in March 2024 to 3.17 in June 2025. This coincided with a decline in the share price from US$127.51 to US$80.79. Sales per share also experienced a slight increase during this period, but not enough to offset the share price decline and thus contributing to the decreasing ratio.
Final Period (Sep 30, 2025 – Dec 31, 2025)
The P/S ratio experienced a rebound in the latter half of 2025, increasing to 4.71 by December 31, 2025. This increase was driven by a substantial rise in the share price to US$123.93, while sales per share continued to increase modestly. This suggests a renewed investor interest or a correction in the previous decline.

Overall, the P/S ratio demonstrated sensitivity to changes in both share price and sales per share. The observed fluctuations suggest that investor sentiment and market conditions played a significant role in the valuation of the company during the analyzed period.


Price to Book Value (P/BV)

Merck & Co. Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
No. shares of common stock outstanding1 2,472,392,003 2,482,022,536 2,497,783,211 2,511,031,253 2,526,036,240 2,529,635,645 2,534,809,312 2,532,806,307 2,532,643,872 2,534,023,084 2,537,521,169 2,537,435,954 2,538,592,467 2,535,395,974 2,533,279,845 2,528,805,025
Selected Financial Data (US$)
Total Merck & Co., Inc. stockholders’ equity (in millions) 52,606 51,850 48,993 48,335 46,313 44,502 43,582 40,364 37,581 41,246 38,693 46,834 45,991 44,458 43,243 40,883
Book value per share (BVPS)2 21.28 20.89 19.61 19.25 18.33 17.59 17.19 15.94 14.84 16.28 15.25 18.46 18.12 17.53 17.07 16.17
Share price1, 3 123.93 84.39 80.79 83.18 91.43 100.73 112.31 127.51 128.84 103.38 106.09 117.68 109.89 98.75 87.41 88.01
Valuation Ratio
P/BV ratio4 5.82 4.04 4.12 4.32 4.99 5.73 6.53 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 229.63 102.40 58.73 48.87 36.12 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59
Amgen Inc. 22.99 17.91 20.63 24.36 26.61 22.86 28.34 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87
Bristol-Myers Squibb Co. 6.61 5.01 5.06 5.70 6.98 6.60 6.01 5.49 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07
Danaher Corp. 2.82 3.05 2.60 2.70 3.00 3.68 3.82 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36
Eli Lilly & Co. 36.91 33.55 33.19 47.74 57.93 56.45 59.24 57.94 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75
Gilead Sciences Inc. 8.07 6.85 6.96 6.42 7.36 6.36 5.15 4.61 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91
Johnson & Johnson 7.12 5.86 5.20 4.79 5.30 5.69 5.37 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36
Pfizer Inc. 1.78 1.49 1.59 1.50 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37
Regeneron Pharmaceuticals Inc. 2.62 2.22 1.98 2.09 2.67 3.14 4.27 3.83 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65
Thermo Fisher Scientific Inc. 3.62 4.18 3.46 3.24 4.09 4.36 4.96 4.80 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23
Vertex Pharmaceuticals Inc. 6.69 6.18 5.60 7.01 7.24 8.24 8.64 5.71 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
BVPS = Total Merck & Co., Inc. stockholders’ equity ÷ No. shares of common stock outstanding
= 52,606,000,000 ÷ 2,472,392,003 = 21.28

3 Closing price as at the filing date of Merck & Co. Inc. Quarterly or Annual Report.

4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= 123.93 ÷ 21.28 = 5.82

5 Click competitor name to see calculations.


The price-to-book value (P/BV) ratio exhibited fluctuating behavior over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated a moderate increase, followed by periods of decline and subsequent recovery.

Initial Trend (Mar 31, 2022 – Dec 31, 2022)
The P/BV ratio began at 5.44 and generally increased to 6.07 by the end of 2022. This suggests a growing investor confidence in the company’s valuation relative to its book value during this timeframe. The increase, while present, was not dramatic, indicating a measured response.
Volatility and Decline (Mar 31, 2023 – Dec 31, 2023)
The first three quarters of 2023 saw significant volatility. The ratio peaked at 6.96 in June 2023, but then decreased to 8.68 by December 2023. This period suggests increased market sensitivity or potentially negative news impacting investor perception of the company’s value relative to its net asset value.
Subsequent Decline and Stabilization (Mar 31, 2024 – Sep 30, 2025)
From March 2024 through September 2025, the P/BV ratio experienced a notable decline, reaching a low of 4.04 in September 2025. This indicates a substantial decrease in the market’s willingness to pay for each dollar of the company’s book value. However, the ratio rebounded to 5.82 by December 31, 2025, suggesting a potential stabilization or renewed investor interest towards the end of the period.

Throughout the observed period, the P/BV ratio remained generally above 4.0, indicating that the market consistently valued the company at more than its book value. However, the pronounced fluctuations and the ultimate decline to a low of 4.04 warrant further investigation into the underlying factors driving these changes. The final increase in December 2025 could signal a turning point, but continued monitoring is necessary to confirm a sustained upward trend.

Book Value per Share Trend
The book value per share generally increased over the period, from $16.17 to $21.28. This upward trend in book value did not consistently translate into a higher P/BV ratio, suggesting that market sentiment and other factors played a significant role in the observed fluctuations.